SUBSEQUENT EVENTS	6 Months Ended
Jun. 30, 2025
Subsequent Events [Abstract]
SUBSEQUENT EVENTS	SUBSEQUENT EVENTS Collaboration and License Agreement with Kissei Pharmaceutical Co., Ltd. In July 2025, the Company and Kissei Pharmaceutical Co., Ltd. (“Kissei”) entered into a collaboration and license agreement (the “Kissei Collaboration and License Agreement”) pursuant to which the Company granted to Kissei an exclusive license to develop and commercialize products containing veligrotug and VRDN-003 for potential treatments, including treatment of TED, in Japan, and a non-exclusive license to manufacture such licensed products worldwide for use in Japan under certain limited circumstances. Under the terms of the Kissei Collaboration and License Agreement, the Company will receive an upfront payment of $70.0 million and will be eligible to receive up to an additional $315.0 million upon the achievement of certain development, regulatory and sales milestones, as well as tiered royalties in percentages ranging from the twenties to the mid-thirties based on future net sales of licensed products in Japan as set forth in the Kissei Collaboration and License Agreement.

SUBSEQUENT EVENTS

6 Months Ended

Jun. 30, 2025

Collaboration and License Agreement with Kissei Pharmaceutical Co., Ltd.

In July 2025, the Company and Kissei Pharmaceutical Co., Ltd. (“Kissei”) entered into a collaboration and license agreement (the “Kissei Collaboration and License Agreement”) pursuant to which the Company granted to Kissei an exclusive license to develop and commercialize products containing veligrotug and VRDN-003 for potential treatments, including treatment of TED, in Japan, and a non-exclusive license to manufacture such licensed products worldwide for use in Japan under certain limited circumstances.

Under the terms of the Kissei Collaboration and License Agreement, the Company will receive an upfront payment of $70.0 million and will be eligible to receive up to an additional $315.0 million upon the achievement of certain development, regulatory and sales milestones, as well as tiered royalties in percentages ranging from the twenties to the mid-thirties based on future net sales of licensed products in Japan as set forth in the Kissei Collaboration and License Agreement.